CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...